Article
Pretreatment HDL-C and ApoA1 are predictive biomarkers of progression-free survival in patients with EGFR mutated advanced non-small cell lung cancer treated with TKI.
Thoracic cancer - 1 Apr 2022
Ma Juan, Bai Ying, Liu Mei, Jiao Tong, Chen Yang, Yuan Bo, Liu Boxuan, Zeng Lizhong, Ming Zongjuan, Li Wei, Sun Ruiying, Yang Xia, Yang Shuanying
Abstract excerpt
BACKGROUND: We aimed to explore the correlation between blood lipids (high density lipoprotein cholesterol [HDL-C] and apolipoprotein A1 [ApoA1]) and epidermal growth factor receptor (EGFR) T790M mutation, as well as its predictive role in clinical efficacy and progression-free survial (PFS) in advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKI). METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.